Epigenetic-Genetic Chromosome Dosage Approach for Fetal Trisomy 21 Detection Using an Autosomal Genetic Reference Marker

Background The putative promoter of the holocarboxylase synthetase (HLCS) gene on chromosome 21 is hypermethylated in placental tissues and could be detected as a fetal-specific DNA marker in maternal plasma. Detection of fetal trisomy 21 (T21) has been demonstrated by an epigenetic-genetic chromosome dosage approach where the amount of hypermethylated HLCS in maternal plasma is normalized using a fetal genetic marker on the Y chromosome as a chromosome dosage reference marker. We explore if this method can be applied on both male and female fetuses with the use of a paternally-inherited fetal single nucleotide polymorphism (SNP) allele on a reference chromosome for chromosome dosage normalization. Methodology We quantified hypermethylated HLCS molecules using methylation-sensitive restriction endonuclease digestion followed by real-time or digital PCR analyses. For chromosome dosage analysis, we compared the amount of digestion-resistant HLCS to that of a SNP allele (rs6636, a C/G SNP) that the fetus has inherited from the father but absent in the pregnant mother. Principal Findings Using a fetal-specific SNP allele on a reference chromosome, we analyzed 20 euploid and nine T21 placental tissue samples. All samples with the fetal-specific C allele were correctly classified. One sample from each of the euploid and T21 groups were misclassified when the fetal-specific G allele was used as the reference marker. We then analyzed 33 euploid and 14 T21 maternal plasma samples. All but one sample from each of the euploid and T21 groups were correctly classified using the fetal-specific C allele, while correct classification was achieved for all samples using the fetal-specific G allele as the reference marker. Conclusions As a proof-of-concept study, we have demonstrated that the epigenetic-genetic chromosome dosage approach can be applied to the prenatal diagnosis of trisomy 21 for both male and female fetuses.

[1]  Charles R Cantor,et al.  Plasma placental RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detection , 2007, Nature Medicine.

[2]  R. Yuen,et al.  Hypermethylation of RASSF1A in human and rhesus placentas. , 2007, The American journal of pathology.

[3]  C. Cantor,et al.  Non-invasive prenatal diagnosis by single molecule counting technologies. , 2009, Trends in genetics : TIG.

[4]  C. Ding,et al.  Systematic search for placental DNA-methylation markers on chromosome 21: toward a maternal plasma-based epigenetic test for fetal trisomy 21. , 2008, Clinical chemistry.

[5]  C. Ding,et al.  Noninvasive prenatal detection of trisomy 21 by an epigenetic-genetic chromosome-dosage approach. , 2010, Clinical chemistry.

[6]  H. C. Fan,et al.  Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood , 2008, Proceedings of the National Academy of Sciences.

[7]  E. Gerdts.  Letter: Cervical cancer and gonorrhoea. , 1974, Lancet.

[8]  K. McKernan,et al.  Maternal plasma DNA analysis with massively parallel sequencing by ligation for noninvasive prenatal diagnosis of trisomy 21. , 2010, Clinical chemistry.

[9]  C. Cantor,et al.  Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma , 2008, Proceedings of the National Academy of Sciences.

[10]  R. Chiu,et al.  mRNA of placental origin is readily detectable in maternal plasma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[11]  N. Carter,et al.  Sites of differential DNA methylation between placenta and peripheral blood: molecular markers for noninvasive prenatal diagnosis of aneuploidies. , 2009, The American journal of pathology.

[12]  Tak Y. Leung,et al.  Digital PCR for the molecular detection of fetal chromosomal aneuploidy , 2007, Proceedings of the National Academy of Sciences.

[13]  D. Sahota,et al.  Risk factors for procedure‐related fetal losses after mid‐trimester genetic amniocentesis , 2006, Prenatal diagnosis.

[14]  Chunming Ding,et al.  Hypermethylated RASSF1A in maternal plasma: A universal fetal DNA marker that improves the reliability of noninvasive prenatal diagnosis. , 2006, Clinical chemistry.

[15]  A. Rudnicka,et al.  First-trimester or second-trimester screening, or both, for Down's syndrome. , 2005, New England Journal of Medicine.

[16]  R. Chiu,et al.  Innovations: Prenatal diagnosis: progress through plasma nucleic acids , 2007, Nature Reviews Genetics.

[17]  K. Nicolaides,et al.  Synergy of total PLAC4 RNA concentration and measurement of the RNA single-nucleotide polymorphism allelic ratio for the noninvasive prenatal detection of trisomy 21. , 2010, Clinical chemistry.

[18]  C. Ding,et al.  Placenta-Derived Fetal Specific mRNA Is More Readily Detectable in Maternal Plasma than in Whole Blood , 2009, PloS one.

[19]  L. Poon,et al.  Clinical Chemistry 47:9 1607–1613 (2001) Molecular Diagnostics and Genetics Effects of Blood-Processing Protocols on Fetal and Total DNA Quantification in Maternal Plasma , 2001 .

[20]  A. Benachi,et al.  New strategy for prenatal diagnosis of X-linked disorders. , 2002, The New England journal of medicine.

[21]  T K Lau,et al.  Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. , 1998, American journal of human genetics.

[22]  T. Leung,et al.  Non‐invasive prenatal detection of fetal trisomy 18 by RNA–SNP allelic ratio analysis using maternal plasma SERPINB2 mRNA: a feasibility study , 2009, Prenatal diagnosis.

[23]  R. Snijders,et al.  First-trimester screening for trisomies 21 and 18. , 2004, The New England journal of medicine.

[24]  G. Daniels,et al.  Noninvasive prenatal diagnosis of fetal blood group phenotypes: current practice and future prospects , 2009, Prenatal diagnosis.

[25]  K. Kinzler,et al.  Digital PCR. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[26]  R. Chiu,et al.  Prenatal diagnosis: progress through plasma nucleic acids. , 2007, Nature reviews. Genetics.

[27]  C. Ding,et al.  Noninvasive prenatal detection of fetal trisomy 18 by epigenetic allelic ratio analysis in maternal plasma: Theoretical and empirical considerations. , 2006, Clinical chemistry.

[28]  Ann Tabor,et al.  RANDOMISED CONTROLLED TRIAL OF GENETIC AMNIOCENTESIS IN 4606 LOW-RISK WOMEN , 1986, The Lancet.

[29]  N M Hjelm,et al.  Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. , 1998, The New England journal of medicine.

[30]  Tze Kin Lau,et al.  Microfluidics digital PCR reveals a higher than expected fraction of fetal DNA in maternal plasma. , 2008, Clinical chemistry.

[31]  F. Crea,et al.  Candidate epigenetic biomarkers for non-invasive prenatal diagnosis of Down syndrome. , 2007, Reproductive biomedicine online.

[32]  M. Blankenstein,et al.  Detection of chromosome 21-encoded mRNA of placental origin in maternal plasma. , 2003, Clinical chemistry.

[33]  C. Ding,et al.  Mass spectrometric detection of an SNP panel as an internal positive control for fetal DNA analysis in maternal plasma. , 2007, Clinical chemistry.

[34]  Chunming Ding,et al.  Detection of the placental epigenetic signature of the maspin gene in maternal plasma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[35]  I. Sargent,et al.  Presence of fetal DNA in maternal plasma and serum , 1997, The Lancet.